Yingjie Zhang
+
Gender:Male
Education Level:Postgraduate (Doctoral)
Alma Mater:山东大学
Paper Publications
- [51] Yingjie Zhang and xuwenfang. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. Bioorg. Med. Chem., 2016.
- [52] Yingjie Zhang and xuwenfang. Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU. Med. Chem., 2016.
- [53] Yingjie Zhang and xuwenfang. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. Eur. J. Med. Chem., 2015.
- [54] Yingjie Zhang and xuwenfang. Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro.. Bioorg. Med. Chem., 2015.
- [55] Yingjie Zhang. Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity. Bioorg. Med. Chem., 2015.
- [56] Yingjie Zhang and xuwenfang. Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. Drug Discov. Ther., 2015.
- [57] Yingjie Zhang and xuwenfang. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr. Drug Targets, 2014.
- [58] Yingjie Zhang and xuwenfang. Discovery of the First N-hydroxycinnamamide-based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity. J. Med. Chem., 2014.
- [59] Yingjie Zhang. Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. Bioorg. Med. Chem., 2016.
- [60] Yingjie Zhang and zhangcai. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest. Anti-Cancer Drugs, 2014.